| Expression pattern: |
UP |
| Associated gene: |
ESR1, MAVS, RIGI |
| Associated microRNA: |
miR‐181a‐2‐3p, miR‐6715b‐5p |
| Biological function: |
promotes ERalpha‐positive breast cancer cell growth and tumorigenesis; promotes endocrine therapy resistance; inhibits anti-tumor immunity |
| Molecular mechanism: |
ceRNA sponging miR‐181a‐2‐3p to stabilize ESR1 mRNA and activate estrogen/ERalpha-target genes; direct interaction with MAVS to disrupt RIGI-MAVS complex and inhibit type I IFN signaling |
| Biological pathway or process: |
proliferation (promotes); drug resistance (promotes); STING/IFN (inhibits); immune regulation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; circRNA-seq; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Western Blot; Co-IP; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
may serve as a diagnostic biomarker and therapeutic target for ERalpha‐positive breast cancer in the clinic |
| Description: |
circPVT1 is up-regulated in breast cancer (including ERalpha-positive tumors) and promotes ERalpha-positive breast tumorigenesis and endocrine therapy resistance. Mechanistically, it sponges miR-181a-2-3p to increase ESR1/ERalpha signaling and directly binds MAVS to block RIGI-MAVS complex formation, suppressing type I IFN signaling and anti-tumor immunity; ASO-mediated circPVT1 inhibition suppresses tumor growth and re-sensitizes tamoxifen-resistant cells. |
| Confidence score: |
0.8785 |